[12] Patent
[11] Patent No.:GC0009442  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/142072
Date of the Decision to Grant the Patent:23/Dec/2018

[21] Application No.:GCC/P/2008/11195

[22] Filing Date:29/6/2008

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
29/6/2007
30/6/2008
60/947,291
12/164,762

[72] Inventors:1- Weirong Chen،2- Jennifer Cossrow،3- Lloyd Franklin،4- Bing Guan،5- John Howard Jones،6- Gnanasambandam Kumaravel،7- Benjamin Lane،8- Adam Littke،9- Alexey Lugovskoy،10- Hairuo Peng،11- Noel Powell،12- Brian Raimundo،13- Hiroko Tanaka،14- Jeffrey Vessels،15- Zhili Xin،16- Thomas Wynn

[73] Owners:1- Sunesis Pharmaceuticals,Inc, 341 Oyster Point Boulevard, South San Fancisco, California 94080, USA،2- Millennium Pharmaceuticals, Inc, 40 Landsdowne Street, Cambridge, Massachussets 02139, USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: C07D401/12, 401/14, 417/12, 471/04; A61K31/506; A61P29/00, 35/00 (2006.01)

[56] Cited Documents:

-ROGER A. SMITH et al.: Recent Advances in the Research and development of RAF Kinase Inhibitors, CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, vol. 6, PAGE 1071 – 1089
-WO 2006065703 A (SUNESIS PHARMACEUTICALS INC [US]; OSLOB JOHAN D [US]; ZHU JIANG [US];) 22 June 2006
-WO 2005082367 A (DEVGEN NV [BE]; LEYSEN DIRK CASIMIR MARIA [BE]; DEFERT OLIVIER RAYNALD) 9 September 2005
 
Examiner: PH. Ahlam S. AlMusallam

[54] COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
[57] Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf–mediated diseases.
No. of claims: 48


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.